Company news

Microbix Biosystems Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

New Larger Manufacturing Plant Ensures Microbix Will Continue to Meet Growing Demand for its Virology Products

April 22, 2008

Microbix Announces First Quarter Results

February 13, 2008

ImaRx and Microbix sign Letter of Intent to manufacture and further develop the FDA-approved clot-dissolving drug, Abbokinase(R)

January 22, 2008

Microbix Announces Year-End Results, Continuing Progress in Major Product Development

December 21, 2007

Microbix Signs Letters of Intent to License its Flu Vaccine Yield Enhancement Technology

December 14, 2007

Microbix Biosystems' CEO visits China to formalize the licensing agreement for the Company's SST technology and to discuss other business opportunities

November 13, 2007

Microbix Biosystems Completes $6.825 Million Private Placement

November 13, 2007

Microbix Biosystems granted U.S. patent for its influenza vaccine yield enhancement technology

October 22, 2007

ALS Therapy Development Institute Signs Manufacturing Agreement with Microbix

October 16, 2007

Microbix Hires Dr. Andre Uddin of BioStrategy Management

September 28, 2007

Microbix Announces Third Quarter Results

August 14, 2007

Microbix mobilizes SWATT team to help companies worldwide expand flu vaccine production

August 13, 2007

Microbix licenses its animal reproduction technology in China

June 27, 2007

Canadian company Microbix showcases vaccine yield enhancement discovery at world's largest conference on influenza

June 18, 2007

Market Regulation Services - Trade Resumption - Microbix Biosystems Inc. - MBX

June 12, 2007

Microbix identifies specific proteins that allow X and Y sperm cells to be separated; files for provisional patent

June 12, 2007

Market Regulation Services - Trading Halt - Microbix Biosystems Inc. - MBX

June 12, 2007

Canadian company Microbix' discovery could save many lives in flu pandemic; its technology to be granted U.S. patent

May 30, 2007

Microbix Announces Second Quarter Results and Provides Update on Product Development

May 15, 2007

Microbix Biosystems Completes Non-Brokered Private Placement Financing For Gross Proceeds of $1.05 Million

April 20, 2007

Microbix Provides Update on Urokinase Project Financing

March 28, 2007

Microbix granted patent on its Vaccine Technology

March 21, 2007

Microbix arranges $500,000 in additional financing for its potential blockbuster biological products

February 20, 2007

Microbix' first quarter results reflect continued substantial investments in its proprietary products

February 14, 2007

Microbix Announces Changes To Board of Directors

February 13, 2007

Microbix Realigns Executive Management Team To Support Revenue Growth and Accelerate Commercialization

January 10, 2007

Microbix Announces Fiscal 2006 Results: Year Highlighted By Sales Growth, Product And Infrastructure Investment, And Independent Confirmation Of Its Flu Vaccine Technology

December 15, 2006

Microbix Updates Plans For Urokinase With Angiogen LLC

November 2, 2006

Financing Announced For Ongoing Development Of Large Market Pipeline

October 17, 2006

Microbix Completes Continuous Disclosure Review With Ontario Securities Commission

September 7, 2006

Microbix' third quarter results reflect continued significant investment in its three proprietary, large-market products

August 14, 2006

Microbix Establishes Key Global Distribution Agreements for its SST(TM) Sperm Sexing Technology for the Dairy, Beef and Swine Industries

July 11, 2006

Microbix and Angiogen seek funding for clinical trials; remission of cancer already observed in early studies; patented therapy destroys tumors by 'starving them' of the nutrients to survive and grow

June 27, 2006

Independent Laboratory Confirms that Microbix' Proprietary Vaccine Technology Significantly Boosts Production of Human Flu Virus From Eggs

June 1, 2006

Powered by strong sales of virology products, Microbix continues to move forward in the development of its proprietary technologies

May 15, 2006

Now there's something you CAN do to prepare for a flu pandemic: Pandemic Response Plan and ToolKit(TM) developed by Microbix now available to consumers and businesses

April 20, 2006

Microbix enters agreement with Angiogen to commercialize a proprietary technology that uses urokinase product for treating cancer

April 4, 2006

Interim Results of Independent Evaluation Confirm That Microbix' Flu Vaccine Technology Works

March 14, 2006

Microbix announces core product sales increase in first quarter, development of new high-value business opportunities

February 15, 2006

Microbix completes financing for its new state-of-the-art drug manufacturing facility in Toronto

February 9, 2006

Microbix takes over production of urokinase, and is currently negotiating the exclusive right to manufacture the drug for a new proprietary use

January 31, 2006

Microbix Announces Fiscal 2005 Results: Year Highlighted By Sales Growth, Profitability, Infrastructure Investment And Acquisition Of A High-Value Technology

December 7, 2005

Preparing For The Pandemic: Microbix Makes Its Response Plan Freely Available To Other Employers and Employees

December 6, 2005

Microbix Announces Independent Evaluation Of Its Vaccine Yield Enhancement Technology

December 6, 2005

Technology that can pre-determine the sex of cattle and swine livestock is acquired by Microbix. Sperm-sexing technology expected to be a major breakthrough

September 30, 2005

Microbix Biosystems Seeks Independent Validation Of Vaccine Technology

September 23, 2005

Microbix announces update on vaccine technology

September 8, 2005

Microbix announces 54% gain in revenue, continued profitability in Third Quarter

August 11, 2005

Microbix announces extension of agreement with major vaccine producer

June 24, 2005

Microbix Announces 24% Increase in Revenue and Improved Earnings in Second Quarter

May 12, 2005

← Newer news releases

Calls

The 5 newest of 12 calls. Every call is listed under its year.

Decks

The 5 newest of 7 decks. Every deck is listed under its year.